Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs
Authors: Samer Al Hadidi, Martha Mims, Courtney Nicole Miller-Chism, Rammurti Kamble
Journal: Annals of Internal Medicine (2020)

Letters18 August 2020Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer DrugsCorrection(s) for this article:CorrectionsJun 2021Correction: Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer DrugsFREESamer Al Hadidi, MD, MS, Martha Mims, MD, PhD, Courtney Nicole Miller-Chism, MD, and Rammurti Kamble, MDSamer Al Hadidi, MD, MSBaylor College of Medicine, Houston, Texas (S.A., M.M., C.N.M., R.K.), Martha Mims, MD, PhDBaylor College of Medicine, Houston, Texas (S.A., M.M., C.N.M., R.K.), Courtney Nicole Miller-Chism, MDBaylor College of Medicine, Houston, Texas (S.A., M.M., C.N.M., R.K.), and Rammurti Kamble, MDBaylor College of Medicine, Houston, Texas (S.A., M.M., C.N.M., R.K.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-0410 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: In the United States, African American persons have the highest death rate and lowest survival rate of any racial or ethnic group for most types of cancer. Socioeconomic factors have been blamed for racial disparities in cancer outcomes (1). However, studies have shown that differences persist despite risk stratification for socioeconomic status and access to care, suggesting that patient comorbid conditions, differences in tumor biology, and underrepresentation of minorities in clinical trials may play a role. For example, certain types of cancer, such as multiple myeloma and prostate cancer, are more common in African American persons, yet landmark trials ...References1. Bach PB, Schrag D, Brawley OW, et al. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287:2106-2113. [PMID: 11966385] CrossrefMedlineGoogle Scholar2. Zeng C, Wen W, Morgans AK, et al. Disparities by race, age, and sex in the improvement of survival for major cancers: results from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1990 to 2010. JAMA Oncol. 2015;1:88-96. [PMID: 26182310] doi:10.1001/jamaoncol.2014.161 CrossrefMedlineGoogle Scholar3. Rivers D, August EM, Sehovic I, et al. A systematic review of the factors influencing African Americans' participation in cancer clinical trials. Contemp Clin Trials. 2013;35:13-32. [PMID: 23557729] doi:10.1016/j.cct.2013.03.007 CrossrefMedlineGoogle Scholar4. Eltayeb AE, Demas DM, Clarke R, et al. The unfolded protein response may contribute to racial disparity in endocrine responsiveness in breast cancer [Abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, Pennsylvania, 18–22 April 2015. Cancer Res. 2015;75(15 Suppl). Abstract no. 1258. doi:10.1158/1538-7445.AM2015-1258 Google Scholar5. Niranjan SJ, Martin MY, Fouad MN, et al. Bias and stereotyping among research and clinical professionals: perspectives on minority recruitment for oncology clinical trials. Cancer. 2020;126:1958-1968. [PMID: 32147815] doi:10.1002/cncr.32755 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine, Houston, Texas (S.A., M.M., C.N.M., R.K.)Presented in part at the 55th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 31 May to 4 June 2019; the Texas Society of Clinical Oncology 2019 Annual Conference, San Antonio, Texas, 14 September 2019; the 2019 Society of Hematologic Oncology Annual Meeting, Houston, Texas, 11 to 14 September 2019; and the San Antonio Breast Cancer Symposium 2019, San Antonio, Texas, 11 to 14 December 2019.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-0410.Reproducible Research Statement: Study protocol, statistical code, and data set: Available from Dr. Al Hadidi (e-mail, [email protected]edu).Corresponding Author: Samer Al Hadidi, MD, MS, Section of Hematology and Oncology, Baylor College of Medicine, Alkek Building for Biomedical Research, One Baylor Plaza, Fourth Floor, Houston, TX 77030; e-mail, [email protected]edu.Correction: This article was corrected on 17 March 2021 to update the disclosures for one of the authors.This article was published at Annals.org on 23 June 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCorrection: Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs Metrics Cited byCommentary: "Multimodality advanced cardiovascular and molecular imaging for early detection and monitoring of cancer therapy-associated cardiotoxicity and the role of artificial intelligence and big data""There's not enough studies": Views of black breast and ovarian cancer patients on research participationTwenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trialsReimagining diversity in multiple myeloma clinical trialsGeographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple MyelomaCancer statistics for African American/Black People 2022Clinical Trial Eligibility Criteria: A Structural Barrier to Diversity in Clinical Trial EnrollmentEnrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant NeoplasmsAssociation of Race With Receipt of Proton Beam Therapy for Patients With Newly Diagnosed Cancer in the US, 2004-2018Diversity in modern heart failure trials: Where are we, and where are we goingA/B design testing of a clinical trial recruitment website: A pilot study to enhance the enrollment of older adultsRace reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006–2020Disparities in Surgical Oncology: Management of Advanced CancerHealth disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based studyAddressing racial/ethnic disparities in cancer clinical trials: Everyone has a role to playCorrection: Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer DrugsRacial and Ethnic Disparities in Cardio-OncologyThe Ethical Imperative of Equity in Oncology: Lessons Learned From 2020 and a Path ForwardRace as a Contributor to Stromal Modulation of Tumor ProgressionLevel of evidence for FDA drug approvals in pivotal clinical trials of hematological malignanciesParticipation of Black Americans in Cancer Clinical Trials: Current Challenges and Proposed SolutionsCardio-Oncology Preventive Care: Racial and Ethnic Disparities 18 August 2020Volume 173, Issue 4Page: 320-322KeywordsAfrican American peopleBreast cancerClinical trialsDrugsFood and Drug AdministrationHematologic malignanciesPopulation statisticsProstate diseasesRacial and ethnic issuesStatistical data ePublished: 23 June 2020 Issue Published: 18 August 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...